Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
Clinical trial NCT01520519 · COMPLETED
Trial details
- NCT number
- NCT01520519
- Sponsor
- M.D. Anderson Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-02-27
- Primary completion
- 2018-08-09
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.